Halozyme's Earnings Growth and Institutional Support Drive Share Price to Near All-Time Highs
Halozyme reported record Q1 fiscal 2026 revenue of $377 million, a 42% year-over-year increase, along with strong non-GAAP diluted earnings per share growth. The company raised its full-year guidance and has seen significant institutional buying activity, contributing to a 52% rise in shares this year.
Tickers: $HALO
Topics: institutional investment pharmaceuticals stock performance